Shares of Biocon is trading higher by 1% at Rs 389, extending its previous day’s over 3% rally, after the company said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.
"The company has received market authorisation from the Drug Controller General of India (DCGI) for its biosimilar trastuzumab being developed jointly with Mylan for the treatment of Her 2+ metastatic breast cancer," Biocon said in a statement.
The stock opened at Rs 388 and touched high of Rs 390, also its 52-week high on the NSE. A combined 202,000 shares have changed hands on the counter so far on the NSE and BSE.
"The company has received market authorisation from the Drug Controller General of India (DCGI) for its biosimilar trastuzumab being developed jointly with Mylan for the treatment of Her 2+ metastatic breast cancer," Biocon said in a statement.
The stock opened at Rs 388 and touched high of Rs 390, also its 52-week high on the NSE. A combined 202,000 shares have changed hands on the counter so far on the NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%